The 20 references in paper П. Лагута С., О. Каткова В., А. Добровольский Б., Е. Титаева В., Е. Панченко П. (2014) “ЗНАЧЕНИЕ ОСТАТОЧНОЙ РЕАКТИВНОСТИ ТРОМБОЦИТОВ НА ТЕРАПИИ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТОЙ У БОЛЬНЫХ СТАБИЛЬНОЙ ИБС (РЕЗУЛЬТАТЫ ПЯТИЛЕТНЕГО НАБЛЮДЕНИЯ)” / spz:neicon:aterotromboz:y:2014:i:2:p:43-57

1
McConnel H. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002, 324: 71–86.
(check this in PDF content)
2
Snoep JD, Hovens MM et al. Association of laboratorydefined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern Med, 2007, 167: 1593–9.
(check this in PDF content)
3
McKee SA, Sane DS, Deliargyris EN. Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance. Thromb Haemost., 2002, 88: 711–5.
(check this in PDF content)
4
Patrono C. Aspirin resistance. definition, mechanism and clinical read-outs. J. Thromb Haemost, 2003, 1: 1710–13.
(check this in PDF content)
5
Krasopoulos G, Brister SJ, Buchanan MR. Aspirin «resistance» and risk of morbidity: systematic review and meta-analysis. Br. Med. J., 2008, 336: 195–8.
(check this in PDF content)
6
Stone GW, Witzenbichler B et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614–23.
(check this in PDF content)
7
Pettersen AA, Seljeflot I, Abdeinoor M, Arnesen H. High on-aspirin platelet reactivity and clinical outcome in patient with stable coronary artery disease: results from ASCEN (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J. Am. Heart Assoc, 2012: e000703.
(check this in PDF content)
8
Born GVR. Quantitative investigation into the aggregation of blood platelets. J. Physiol.(Lond), 1962, 162: 67–68.
(check this in PDF content)
9
Reich LM, Heiss G et al. Ancle-brachial index and hemostatic markers in the Atherosclerosis Risk in Communities (ARIC) study cohort. Vasc. Med,2007, 12 (4): 267–73.
(check this in PDF content)
10
Lee AJ, Fowkes GR, Lowe GD, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler. Thromb. Vasc. Biol.,1995, 15 (8): 1094–7.
(check this in PDF content)
11
Stegnar M, Vene N, Bozic M. Do haemostasis activation markers that predict cardiovascular disease exist? Pathophysiol. Haemost. Thromb, 2003/2004, 33: 302–8.
(check this in PDF content)
12
Rumley A, Emberson JR et al. Effects of older age on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60–79 years. Journal of Thrombosis and Haemostasis, 2006, 4 (5): 982–87.
(check this in PDF content)
13
Danesh J, Whincup P et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.Circulation,2001, 103: 2323–7.
(check this in PDF content)
14
Bruno A, McConnell JP, Manbach HH et al. Aspirin and urinary 11-dehydrothromboxane B2 in African American stroke patients. Stroke,2002, 33: 57–60.
(check this in PDF content)
15
Лагута П.С., Каткова О.В., Титаева Е.В., Добровольский А.Б., Деев А.Д., Панченко Е.П. «Резистентность» к аспирину у больных стабильной ИБС. Кардиология, 2010, 11: 4–11
(check this in PDF content)
16
Шалаев С.В., Панченко Е.П., Масенко В.П. и др. Впервые возникшая стенокардия: функциональная активность тромбоцитов. Кардиология,1988, 7: 63–68.
(check this in PDF content)
17
Komarov A, Dobrovolsky A, Karpov Yu, Panchenko EP et al. D-Dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Hear J, 2002, 23 (16): 1309–16.
(check this in PDF content)
18
Lordkipanidze M, Pharand C, Schampaer E et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patient with stable coronary artery disease. Eur Hear J, 2007, 28: 1702–8.
(check this in PDF content)
19
Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Hear J,2011, 32: 2922–32.
(check this in PDF content)
20
Aradi D, Storey RF, Kamocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Hear J, 2014, 35: 209–215.
(check this in PDF content)